Final Program

SUNDAY • MAY 15 109
fellows and established scientists in basic research on lung biology, tuberculosis
pathogenesis, infectious disease, informaticians and systems biology researchers.
Objectives
At the conclusion of this session, the participant will be able to:
• understand the potential impact of the implementation of systems biology;
• learn new findings about the pathobiology of tuberculosis in the human lung;
• apply new learned knowledge to their own ongoing research.
Approximately one-third of the world’s population is latently infected with Mtb with
a 10% risk of developing pulmonary tuberculosis. It is the second highest cause of
death from infectious diseases after HIV/AIDS, and is the biggest killer of people
infected with HIV. The primary route of infection with Mtb is through the lung and
interactions with the host lung defenses determine the course of the disease. This
session will present the overall results from the NHLBI sponsored TB Systems
Biology Program that was conceived with the objective of applying systems
biology approaches to better understand the pathobiology of TB. Results from the
integration of computational modeling strategies, “omics” technologies, and
advances in bioengineering will be presented and how the implementation of such
methodologies can help overcome obstacles in understanding complex
host-mycobacterial interactions and host immune response networks, and helped
to understand the latency and reactivation cycle of TB in the human lung.
Chairing: P.C. Karakousis, MD, Baltimore, MD
E. Caler, PhD, Bethesda, MD
12:15 Novel Approaches to Understanding and Combating Latent TB
Infection
P.C. Karakousis, MD, Baltimore, MD
12:30 Systems Biology of Immune Evasion by M. Tuberculosis
W.H. Boom, MD, Cleveland, OH
12:45 Tuberculosis: Learning from In Vivo and In Silico Models
J. Flynn, PhD, Pittsburgh, PA
1:00 Vitamin D Receptor Signaling in Tuberculosis: Multiple
Systems
H. Salamon, PhD, Berkeley, CA
L9
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE,
DIVISION OF LUNG DISEASES, NIH
BEHAVIOR TO BIOMARKERS: RESEARCH FROM
THE TOBACCO REGULATORY SCIENCE PROGRAM
12:15 p.m. - 1:15 p.m. MOSCONE CENTER
Target Audience
Those with clinical or research responsibilities.
Room 2020/2022 (West Building, Level 2)
Objectives
At the conclusion of this session, the participant will be able to:
• understand and learn about the Tobacco Regulatory Science Program;
• learn about biomarkers of tobacco related pulmonary toxicity;
• learn about the effects of tobacco products on lung health.
With the passage of the 2009 Family Smoking Prevention and Tobacco Control
Act, the FDA acquired the authority to regulate the manufacture, marketing, and
distribution of tobacco products in order to protect human health. Within the
framework of this Act, the NIH and FDA formed an interagency partnership to
foster tobacco regulatory research administered through the Tobacco Regulatory
Science Program (TRSP). Projects supported through TRSP include behavioral,
clinical, animal, and in vitro research. This session will focus on TRSP-supported
research that touches on tobacco products — including cigarettes, cigars,
waterpipe, and e-cigarettes — and their effects on pulmonary health.
Chairing: P. Callahan-Lyon, MD, Silver Spring, MD
L. Postow, PhD, Bethesda, MD
12:15 The Relationship Between Use of Electronic Cigarettes and
Smoking Cigarettes in California Youth
J.M. Samet, MD, MS, Los Angeles, CA
12:27 Improved Models to Inform Tobacco Product Regulation
S. Glantz, PhD, San Francisco, CA
12:39 Disordered Lung Biology Associated with Alternative Tobacco
Use
R.G. Crystal, MD, New York, NY
12:51 PGP: A Possible Biomarker for COPD Exacerbations and/or
Progression
J.M. Wells, MD, Birmingham, AL
1:03 Impact of Tobacco Exposure on the Lung’s Innate Defense
System
R. Tarran, PhD, Chapel Hill, NC
MEET THE PROFESSOR SEMINARS
CME Credits Available: 1.0
Registration Fee: $70.00 (includes box lunch.)
Attendance is limited. Pre-registration is required.
12:15 p.m. - 1:15 p.m. INTERCONTINENTAL HOTEL
MP401
MP402
MP403
MP404
MP405
PROSTAGLANDIN REGULATION OF ASTHMA
R.S. Peebles, MD, Nashville, TN
Union Square (Third Floor)
THE ASTHMA-COPD OVERLAP SYNDROME (ACOS):
INSIGHTS INTO A NEW DISEASE PHENOTYPE
A.A. Zeki, MD, MAS, Sacramento, CA
SoMa (Third Floor)
THE FUTURE OF IPF: WHAT WILL IT LOOK LIKE?
H.R. Collard, MD, San Francisco, CA
L. Richeldi, MD, PhD, Southampton, United Kingdom
Mission (Third Floor)
ALPHA-1 ANTITRYPSIN DEFICIENCY
C.B. Strange, MD, Charleston, SC
Marina (Third Floor)
LUNG AND PLEURAL INFECTIONS: CONTROVERSIES AND
ADVANCES
G.W. Waterer, MBBS, PhD, MBA, Perth, Australia
Y.C.G. Lee, MBChB, PhD, Perth, Australia
Grand Ballroom C (Third Floor)
SUNDAY MID-DAY
ATS 2016 • San Francisco